| Previous Close | 81.7100 |
| Open | 82.1400 |
| Bid | 81.5000 x 1000 |
| Ask | 81.5200 x 200 |
| Day's Range | 81.3601 - 82.1800 |
| 52 Week Range | 64.1800 - 86.7200 |
| Volume | 873,876 |
| Avg. Volume | 3,617,967 |
| Market Cap | 85.2B |
| Beta | 0.15 |
| PE Ratio (TTM) | 39.35 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.55%) |
| Ex-Dividend Date | 2017-08-11 |
| 1y Target Est | N/A |
- Editor's PickYahoo Finance•2 days ago
What Trump has done to lower the ‘RIPOFF DRUG PRICES’ he’s decrying
Trump has decried these price hikes since the campaign. President Donald Trump blasted Merck CEO Kenneth C. Frazier on Monday morning after Frazier announced he was leaving the President’s manufacturing council following Trump’s equivocal response to the neo-Nazi and white nationalist rally in Charlottesville, Virginia. In March, Democratic Representatives Elijah Cummings (MD) and Peter Welch (VT) met with Trump to discuss their bill that would help lower prescription drug prices by allowing regulated drug importation and Medicare’s ability to negotiate wholesale prices for wholesale drugs, instead of retail prices.
- Capital Cube•2 days ago
ETFs with exposure to Eli Lilly & Co. : August 14, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Eli Lilly & Co. Here are 5 ETFs with the largest exposure to LLY-US. Comparing the performance and risk of Eli Lilly & Co. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)
- Zacks•2 days ago
Will Nektar's (NKTR) Candidates Enhance Growth in 2017?
Nektar Therapeutics (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.
